

REFINITIV

# DELTA REPORT

## 10-Q

KTRA - KINTARA THERAPEUTICS, INC

10-Q - DECEMBER 31, 2023 COMPARED TO 10-Q - SEPTEMBER 30, 2023

The following comparison report has been automatically generated

TOTAL DELTAS	602
--------------	-----

 CHANGES	200
---	-----

 DELETIONS	159
---	-----

 ADDITIONS	243
---	-----

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, December 31, 2023

or

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission file number: 001-37823

Kintara Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Nevada

99-0360497

(State or other jurisdiction of  
incorporation or organization)

(I.R.S. Employer  
Identification No.)

9920 Pacific Heights Blvd, Suite 150  
San Diego, CA

92121

(Address of principal executive offices)

(zip code)

(858) 350-4364

(Registrant's telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common Stock	KTRA	The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No ☒

Number of shares of common stock outstanding as of **November 13, 2023** February 12, 2024 was **3,387,808** 39,037,899.

## TABLE OF CONTENTS

	Page No.
<b><u>PART I. - FINANCIAL INFORMATION</u></b>	
Item 1. <a href="#"><u>Financial Statements.</u></a>	1
Item 2. <a href="#"><u>Management’s Discussion and Analysis of Financial Condition and Results of Operations.</u></a>	18
Item 3. <a href="#"><u>Quantitative and Qualitative Disclosures About Market Risk.</u></a>	<b>26</b> 28
Item 4. <a href="#"><u>Controls and Procedures.</u></a>	<b>26</b> 28
<b><u>PART II - OTHER INFORMATION</u></b>	
Item 1. <a href="#"><u>Legal Proceedings.</u></a>	<b>27</b> 29
Item 1A. <a href="#"><u>Risk Factors.</u></a>	<b>27</b> 29
Item 2. <a href="#"><u>Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities.</u></a>	<b>27</b> 29
Item 3. <a href="#"><u>Defaults Upon Senior Securities.</u></a>	<b>28</b> 30
Item 4. <a href="#"><u>Mine Safety Disclosures.</u></a>	<b>28</b> 30

Item 5.	<a href="#">Other Information.</a>	28 30
Item 6.	<a href="#">Exhibits.</a>	29 31

PART 1. - FINANCIAL INFORMATION

Item 1. Financial Statements.

Kintara Therapeutics, Inc.

Condensed Consolidated Interim Financial Statements

(Unaudited)

For the **three** **six** months ended **September 30, 2023** **December 31, 2023**

(expressed in US dollars unless otherwise noted)

Kintara Therapeutics, Inc.

Condensed Consolidated Interim Balance Sheets

(In thousands, except par value amounts)

	Septemb er 30, 2023	June 30, 2023		December 31, 2023	June 30, 2023
No					
te	\$	\$	Note	\$	\$
	(unaudite	d)		(unaudited)	
Assets					
Current assets					
Cash and cash equivalents		1,53			
	216	5		658	1,535
Prepaid expenses, deposits and other	567	660			

Subscriptions receivable				7	103	—
Prepaid expenses, taxes and other receivables					311	660
Clinical trial deposit		1,07				
	3	—	5	3	114	1,075
Total current assets		3,27				
		783	0		1,186	3,270
Property and equipment, net	5	694	709	5	699	709
Total assets		3,97				
		1,477	9		1,885	3,979
Liabilities						
Current liabilities						
Accounts payable and accrued liabilities		2,78				
		2,998	4		1,722	2,784
Related party payables	6	338	298	6	148	298
Total current liabilities		3,08				
		3,336	2		1,870	3,082
Milestone payment liability	9	167	166	9	179	166
Total liabilities		3,24				
		3,503	8		2,049	3,248
Stockholders' equity (deficiency)						
Stockholders' equity						
Preferred stock						
Authorized						
5,000 shares, \$0.001 par value						
5,000 shares, \$0.001 par value						
Issued and outstanding						
279 Series A shares at September 30, 2023 (June 30, 2023 – 279)	7	279	279			
14 Series C shares at September 30, 2023 (June 30, 2023 – 14)	7	10,329	66			
279 Series A shares at December 31, 2023 (June 30, 2023 – 279)	7			7	279	279
14 Series C shares at December 31, 2023 (June 30, 2023 – 14)	7			7	9,973	10,366
Common stock						
Authorized						
75,000 shares at September 30, 2023 (June 30, 2023 - 75,000), \$0.001 par value						
75,000 shares at December 31, 2023 (June 30, 2023 - 75,000), \$0.001 par value						

Issued and outstanding					
1,746 issued at September 30, 2023 (June 30, 2023 – 1,692)	7	2	2		
10,167 issued at December 31, 2023 (June 30, 2023 – 1,692)				7	10 2
Additional paid-in capital	141,85	141,			
	7	5 438		7	145,090 141,438
Accumulated deficit	(154,5	(151,			
	12)	375)		(155,537)	(151,375)
Accumulated other comprehensive income	21	21		21	21
<b>Total stockholders' equity (deficiency)</b>	<u>(2,026)</u>	<u>731</u>			
<b>Total liabilities and stockholders' equity (deficiency)</b>		3,97			
	<u>1,477</u>	<u>9</u>			
<b>Total stockholders' equity</b>				(164)	731
<b>Total liabilities and stockholders' equity</b>				<u>1,885</u>	<u>3,979</u>
<b>Nature of operations, corporate history, going concern and management plans</b> (note 1)					
<b>Subsequent events</b> (note 10)					

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

2

**Kintara Therapeutics, Inc.**  
**Condensed Consolidated Interim Statements of Operations**  
(Unaudited)  
(In thousands, except per share amounts)

	Three months ended September 30,		Note	Three months ended December 31,		Six months ended December 31,	
	No						
	te	2023		2022	2023	2022	2023
Expenses							
Research and development		1,85	3,17				
		\$ 9	\$ 1	\$ 111	\$ 2,059	\$ 1,970	\$ 5,230

General and administrative	1,10	1,47					
	<u>3</u>	<u>5</u>		<u>908</u>	<u>1,440</u>	<u>2,011</u>	<u>2,915</u>
	(2,9	(4,6					
	<u>62)</u>	<u>46)</u>		<u>(1,019)</u>	<u>(3,499)</u>	<u>(3,981)</u>	<u>(8,145)</u>
Other income (loss)							
Foreign exchange	(2)	11		(6)	0	(8)	11
Interest, net	<u>2</u>	<u>39</u>		<u>2</u>	<u>45</u>	<u>4</u>	<u>84</u>
	<u>—</u>	<u>50</u>		<u>(4)</u>	<u>45</u>	<u>(4)</u>	<u>95</u>
Net loss for the period	(2,9	(4,5					
	<u>62)</u>	<u>96)</u>		<u>(1,023)</u>	<u>(3,454)</u>	<u>(3,985)</u>	<u>(8,050)</u>
Computation of basic loss per share							
Net loss for the period	(2,9	(4,5					
	62)	96)		(1,023)	(3,454)	(3,985)	(8,050)
Series A Preferred cash dividend	7	(2)	(2)	7	(2)	(2)	(4)
Series C Preferred stock dividend		(17	(36				
	7	<u>3)</u>	<u>2)</u>	7	<u>—</u>	<u>—</u>	<u>(173)</u>
Net loss for the period attributable to common stockholders	(3,1	(4,9					
	<u>\$ 37)</u>	<u>\$ 60)</u>		<u>\$ (1,025)</u>	<u>\$ (3,456)</u>	<u>\$ (4,162)</u>	<u>\$ (8,416)</u>
Basic and fully diluted loss per share	(1.8	(3.3					
	<u>\$ 3)</u>	<u>\$ 9)</u>		<u>\$ (0.24)</u>	<u>\$ (2.10)</u>	<u>\$ (1.37)</u>	<u>\$ (5.42)</u>
Basic and fully diluted weighted average number of shares	1,71	1,46					
	8	4		4,337	1,643	3,027	1,554

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

**Kintara Therapeutics, Inc.**  
**Condensed Consolidated Interim Statements of Stockholders' Equity (Deficiency)**  
(Unaudited)  
For the **three** **six** months ended **September 30, 2023** **December 31, 2023**  
(In thousands)

	Accumulated other comprehensive income (deficiency)							Total stockholders' equity (deficiency)						
	Number of shares	Common stock	Additional paid-in capital	Accumulated other comprehensive income	Preferred stock	Accumulated deficit		Number of shares	Common stock	Additional paid-in capital	Accumulated other comprehensive income	Preferred stock	Accumulated deficit	Total stockholders' equity
		\$	\$	\$	\$	\$			\$	\$	\$	\$	\$	\$
Balance - June 30, 2023			1			(1								
			4		1	5								
	1,		1,		0,	1,								
	6		4		6	3	7							
	9		3	2	4	7	3							
	2	2	8	1	5	5)	1	1,692	2	141,438	21	10,645	(151,375)	731
Issuance of shares on vesting of restricted stock units	4	—	—	—	—	—	—	4	—	—	—	—	—	—
Conversion of Series C Preferred stock to common stock	1	—	3	—	(3	7)	—	1	—	37	—	(37)	—	—
Stock option expense	—	—	1	—	—	—	1	—	—	—	—	—	—	—
			6				6							
	—	—	0	—	—	—	0	—	—	160	—	—	—	160
Restricted stock unit expense			4				4							
			7	—	—	—	7	—	—	47	—	—	—	47



Series A Preferred cash dividend	—	—	—	—	—	(2)	(2)	—	—	—	—	—	(2)	(2)
Series C Preferred stock dividend	4	—	1	7	—	(1)	7	49	—	173	—	—	(173)	—
Loss for the period	—	—	—	—	—	(2)	(2)	—	—	—	—	—	(2,962)	(2,962)
Balance - September 30, 2023	1,746	2	141,855	21	10,608	(154,512)	(2,026)							
Issuance of shares pursuant to equity line - net of issue costs	400	—	105	—	—	—	105							
Issuance of shares pursuant to ATM - net of issue costs	8,013	8	2,571	—	—	—	2,579							
Conversion of Series C Preferred stock to common stock	8	—	356	—	(356)	—	—							
Stock option expense	—	—	165	—	—	—	165							

Restricted stock unit expense	—	—	38	—	—	—	38
Series A Preferred cash dividend	—	—	—	—	—	(2)	(2)
Loss for the period	—	—	—	—	—	(1,023)	(1,023)
<b>Balance - December 31, 2023</b>	<u>10,167</u>	<u>10</u>	<u>145,090</u>	<u>21</u>	<u>10,252</u>	<u>(155,537)</u>	<u>(164)</u>

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Kintara Therapeutics, Inc.

Condensed Consolidated Interim Statements of Stockholders' Equity

(Unaudited)

For the 

three

six

 months ended 

September 30, 2022

December 31, 2022

(In thousands)

Accumulated other comprehensive income											
Additional paid-in capital						Total					
Number of shares	Common stock	Additional paid-in capital	Preferred stock	Accumulated deficit	Accumulated other comprehensive income	Number of shares	Common stock	Additional paid-in capital	Preferred stock	Accumulated deficit	Total stockholders' equity
\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$	\$

Balance - June 30, 2022			1				(1									
			3		1		3	1								
	1,		5,		2,		6,	1,								
	3		5		5		3	7								
	1		6	1	2	5	5	9								
	1	6	0	1	4	6)	5	1,311	66	135,510		21	12,554	(136,356)	11,795	
Issuance of shares - net of issue costs			1,				1,									
	2		8				9									
	6	1	9				0									
	2	3	0	—	—	—	3	262	13	1,890		—	—	—	1,903	
Stock option expense			5				5									
			1				1									
	—	—	8	—	—	—	8	—	—	518		—	—	—	518	
Series A Preferred cash dividend							(2)	(2)	—	—	—		—	—	(2)	(2)
Series C Preferred stock dividend			3				(3									
	4		6				6									
	3	2	0	—	—	2)	—	43	2	360		—	—	(362)	—	
Loss for the period							(4	(4								
							,5	,5								
							9	9								
	—	—	—	—	—	6)	6)	—	—	—		—	—	(4,596)	(4,596)	
Balance - Septembe r 30, 2022			1				(1									
			3		1		4									
	1,		8,		2,		1,	9,								
	6		2		5		3	6								
	1	8	7	2	5	1	1									
	6	1	8	1	4	6)	8	1,616	81	138,278		21	12,554	(141,316)	9,618	
Conversion of Series C Preferred stock to common stock								42	—	1,778		—	(1,778)	—	—	

Additional shares issued on reverse stock split	15	—	—	—	—	—	—
Stock option expense	—	—	436	—	—	—	436
Series A Preferred cash dividend	—	—	—	—	—	(2)	(2)
Loss for the period	—	—	—	—	—	(3,454)	(3,454)
<b>Balance - December 31, 2022</b>	<b>1,673</b>	<b>81</b>	<b>140,492</b>	<b>21</b>	<b>10,776</b>	<b>(144,772)</b>	<b>6,598</b>

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

5

**Kintara Therapeutics, Inc.**  
**Condensed Consolidated Interim Statements of Cash Flows**  
(Unaudited)  
(In thousands)

	Three months ended September 30,		Note	Six months ended December 31,	
	2023	2022		2023	2022
	\$	\$		\$	\$
<b>Cash flows from operating activities</b>					
Loss for the period	(2,962)	(4,596)		(3,985)	(8,050)

Adjustments to reconcile net loss to net cash used in operating activities						
Amortization of clinical trial deposit				3	—	1,075
Depreciation of property and equipment	5	15	15	5	30	30
Change in fair value of milestone liability		1	(87)		13	(83)
Stock option expense	7	160	518	7	325	954
Restricted stock units and shares issued for services	7	47	—			
Restricted stock unit expense				7	85	—
Changes in operating assets and liabilities						
Prepaid expenses, deposits and other		93	(40)			
Prepaid expenses, taxes and other receivables					349	(48)
Clinical trial deposit		1,0	(1,7			
		75	00)		961	(1,700)
Accounts payable and accrued liabilities		214	(331)		(1,062)	(535)
Related party payables		40	(148)		(150)	(173)
<b>Net cash used in operating activities</b>		(1,3	(6,3			
		17)	69)		(3,434)	(8,530)
<b>Cash flows from investing activities</b>						
Purchase of equipment	5	—	(232)	5	(20)	(232)
<b>Net cash used in investing activities</b>		—	(232)		(20)	(232)
<b>Cash flows from financing activities</b>						
Net proceeds from the issuance of shares and warrants	7	—	1,90			
			8			
Net proceeds from the issuance of shares - equity line				7	105	1,860
Net proceeds from the issuance of shares - ATM				7	2,476	—
Series A Preferred cash dividend	6	(2)	(2)	6	(4)	(4)
<b>Net cash provided by (used in) financing activities</b>			1,90			
		(2)	6			
<b>Net cash provided by financing activities</b>					2,577	1,856
<b>Decrease in cash and cash equivalents</b>		(1,3	(4,6			
		19)	95)		(877)	(6,906)
<b>Cash and cash equivalents – beginning of period</b>		1,5	11,7			
		35	80		1,535	11,780
<b>Cash and cash equivalents – end of period</b>			7,08			
		216	5		658	4,874
<b>Supplementary information (note 7)</b>						
<b>Supplementary information (note 8)</b>						

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

**Kintara Therapeutics, Inc.**  
**Notes to Condensed Consolidated Interim Financial Statements**  
(Unaudited)

September 30, December 31, 2023

(expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted)

**1 Nature of operations, corporate history, and going concern and management plans**

**Nature of operations**

Kintara Therapeutics, Inc. (the "Company") is a clinical-stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing two one late-stage therapeutics therapeutic - VAL-083 for glioblastoma and REM-001 for cutaneous metastatic breast cancer. cancer ("CMBC"). In order to accelerate the Company's development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its current and future product candidates.

**Corporate history**

The Company is a Nevada corporation formed on June 24, 2009, under the name Berry Only, Inc. On January 25, 2013, the Company entered into and closed an exchange agreement (the "Exchange Agreement"), with Del Mar Pharmaceuticals (BC) Ltd. ("Del Mar (BC)"), 0959454 B.C. Ltd. ("Callco"), and 0959456 B.C. Ltd. ("Exchangeco") and the security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del Mar (BC) became a wholly-owned subsidiary of the Company (the "Reverse Acquisition").

On August 19, 2020, the Company completed its merger with Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation ("Adgero") in which Adgero continued its existence under Delaware law and became a direct, wholly-owned subsidiary of the Company. Following the completion of the merger, the Company changed its name from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc. and began trading on The Nasdaq Capital Market LLC ("Nasdaq") under the symbol "KTRA".

Kintara Therapeutics, Inc. is the parent company of Del Mar (BC), a British Columbia, Canada corporation and Adgero which are clinical-stage companies with a focus on the development of drugs for the treatment of cancer. The Company is also the parent company to Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition. In connection with the Adgero merger, the Company also became the parent company of Adgero Biopharmaceuticals, Inc. ("Adgero Bio"), formerly a wholly-owned subsidiary of Adgero.

References to the Company refer to the Company and its wholly-owned subsidiaries.

**Going concern and management plans**

These condensed consolidated interim financial statements have been prepared on a going concern basis which assumes that the Company will continue its operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business.

For the **three** **six** months ended **September 30, 2023** **December 31, 2023**, the Company reported a loss of **\$2,962** **3,985** and a negative cash flow from operations of **\$1,317** **3,434**. The Company had an accumulated deficit of **\$154,512** **155,537** and had cash and cash equivalents of **\$216** **658** as of **September 30, 2023** **December 31, 2023**. The Company is in the clinical stage and has not generated any revenues to date. The Company does not have the prospect of achieving revenues until such time that its product **candidates** **are candidate is** commercialized, or partnered, which may not ever occur. On August 2, 2022, the Company entered into a stock purchase agreement under which the Company **ultimately received approximately** **has issued** 662 shares of common stock for **\$1,903** **2,008** in net proceeds as of **September 30, 2023, which is the current maximum available under the stock purchase agreement.** **December 31, 2023.** In addition, on June 28, 2023, the Company announced that it had been awarded approximately \$2.0 million in grant funding to be received over a **two year** **two-year** period for its REM-001 project. **Subsequent to September 30, 2023** **During the six months ended December 31, 2023,** the Company **raised** **issued** an additional 8,013 shares of common stock for net proceeds of **\$968** **2,579** from its at-the-market ("ATM") facility, and announced that it is suspending the development of VAL-083. Even with the proceeds from the grant funding, the stock purchase financing, and the ATM sales, the Company will require additional funding to maintain its clinical trials, research and development projects, and for general operations. These circumstances indicate substantial doubt exists about the Company's ability to continue as a going concern within one year from the date of filing of these condensed consolidated interim financial statements.

Consequently, management is pursuing various financing alternatives to fund the Company's operations so it can continue as a going concern. Management plans to continue to pursue opportunities to secure the necessary financing through the issue of new equity, **including its ATM facility,** debt, and/or entering into strategic partnership arrangements. However, the Company's ability to raise additional capital could be affected by various risks and uncertainties including, but not limited to, global unrest. The Company

7

may not be able to raise

7

sufficient additional capital and may **need to** tailor its drug candidate development programs based on the amount of funding the Company is able to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful.

These condensed consolidated interim financial statements do not give effect to any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

## 2 Significant accounting policies

### Reverse stock split

On November 10, 2022, the Company filed a Certificate of Change to the Company's Articles of Incorporation, as amended, in order to effectuate a 1:50 reverse stock split (the "Reverse "Reverse Stock Split" Split") of its issued and outstanding common stock as well as its authorized shares of common stock. As a result of the Reverse Stock Split, every 50 shares of issued and outstanding common stock were converted into one share of common stock with a proportionate reduction in the Company's authorized shares of common stock. Any fractional shares of common stock resulting from the Reverse Stock Split were rounded up to the nearest whole post-Reverse Stock Split share. The Reverse Stock Split did not change the par value of the Company's common stock. All outstanding securities entitling their holders to acquire shares of common stock were adjusted as a result of the Reverse Stock Split. All common share and per share data are retrospectively restated to give effect to the Reverse Stock Split for all periods presented herein.

## Basis of presentation

The condensed consolidated interim financial statements of the Company have been prepared in accordance with United States Generally Accepted Accounting Principles ("U.S. GAAP") and are presented in United States dollars. The functional currency of the Company and each of its subsidiaries is the United States dollar.

The accompanying condensed consolidated interim financial statements include the accounts of the Company and its wholly-owned subsidiaries, Adgero, Adgero Bio, Del Mar (BC), Callco, and Exchangeco. All intercompany balances and transactions have been eliminated in consolidation.

The principal accounting policies applied in the preparation of these condensed consolidated interim financial statements are set out below and have been consistently applied to all periods presented.

## Unaudited interim financial data

The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the "SEC" "SEC") for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. GAAP for complete financial statements. These unaudited condensed consolidated interim financial statements should be read in conjunction with the June 30, 2023, audited consolidated financial statements of the Company included in the Company's Form 10-K filed with the SEC on September 18, 2023. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation. The results for three six months ended September 30, 2023 December 31, 2023, are not necessarily indicative of the results to be expected for the fiscal year ending June 30, 2024, or for any other future annual or interim period.

## Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services, milestone payment liability, and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements.

## Loss per share

Income or loss per share is calculated based on the weighted average number of common shares outstanding. For the three-month six-month periods ended September 30, 2023 December 31, 2023, and 2022, diluted loss per share does not differ from basic loss per share since the effect of the Company's warrants, stock options, restricted stock units, and convertible preferred shares is anti-dilutive.



As of September 30, 2023 December 31, 2023, potential common shares of 706 700 (2022 – 714) related to outstanding common share warrants, 42 (2022 – 42) related to outstanding

8

Series C preferred stock warrants, 275 237 (2022 – 246 241) related to stock options, 69 66 (2022 - nil) related to restricted stock

8

units, and 244 235 (2022 – 290 244) relating to outstanding Series C convertible preferred shares were excluded from the calculation of net loss per common share.

### Government assistance

Government grants, including grants from similar bodies, are recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program and there is reasonable assurance that the grant will be received. Grants that compensate the Company for expenses incurred are recognized in income or loss in reduction thereof in the same period in which the expenses are recognized. The Company uses a net presentation basis whereby the grant offsets the research and development expenses as it is being recovered under the grant program.

### Recently issued accounting standards

Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company's condensed consolidated interim financial statements.

## 3 Clinical trial deposit

In October 2020, the Company announced that it had entered into a final agreement with a contract research organization ("CRO") for the management of the Company's registrational study of VAL-083 for glioblastoma. Under the agreement, the Company will supply supplied the drug for the study and the CRO will manage managed all operational aspects of the study including site activation and patient enrollment. The Company is was required to make certain payments under the agreement related to patient enrollment milestones. For the three and six months ended September 30, 2023 December 31, 2023, the Company has recognized \$1 a recovery of \$,075 512 (2022 - \$1,840 1,075 expense) and an expense of \$563 (2022 - \$1,075) of expenses , respectively, for this study in relation to clinical site initiation and patient enrollment.

As of September 30, 2023, the Company has made aggregate deposit payments of \$4,300 to the CRO and has recognized the \$3,225 as an expense in fiscal year 2023. In the three months ended September 30, 2023, the remaining deposit of \$1,075 was offset against amounts owing to the CRO. The Company can terminate the study at any time. Upon termination, the Company will be liable for any payments due to the effective date of the termination as well as any non-refundable costs incurred by the CRO prior to the date of termination.

On October 31, 2023, the Company announced that preliminary topline results from this registrational study for VAL-083 did not perform better than the current standards of care in glioblastoma. As a result, the Company announced that it is suspending has terminated the development of VAL-083. Please see footnote 10 – Subsequent events. In the six months ended December 31, 2023, the remaining deposit of \$1,075 was offset against amounts owing to the CRO and the agreement with the CRO was terminated with an additional final cost of \$1,000, of which \$600 was paid at December 31, 2023, and \$400 was paid subsequent to December 31, 2023.

In the six months ended December 31, 2023, the Company paid \$114 as a deposit with a CRO for the management of the Company's 15-patient study of REM-001 for cutaneous metastatic breast cancer ("CMBC").

#### 4 Clinical trials grant

Effective July 1, 2023, the Company was awarded a \$2,000 Small Business Innovation Research grant from the National Institutes of Health ("NIH") to support the clinical development of REM-001 for the treatment of cutaneous metastatic breast cancer. The grant will be received in two tranches: approximately \$1,250 for the period July 1, 2023, to June 30, 2024, and approximately \$750 for the period July 1, 2024, to June 30, 2025. As a result of receiving the grant, the REM-001, 15-patient clinical trial will be re-started. The grant is expended to the Company as a reimbursement of expenditures incurred. During the three and six months ended September 30, 2023 December 31, 2023, the Company received \$13 197 (2022 - nil) and \$210 (2022 - nil), respectively, for grants received against research and development expenditures in the period.

The grant is subject to various performance conditions and funding risk where the financial conditions of the NIH may change from time to time. The Company recognizes the grant only to the extent there is reasonable assurance the grant will be funded to the Company.

#### 5 Property and equipment, net

	\$ (thousands)
Balance, June 30, 2023	709
Less depreciation Additions	20
Depreciation	(15 30)
Balance, September 30, 2023 December 31, 2023	694 699

9

At September 30, 2023 December 31, 2023, the total capitalized cost of property and equipment was \$859 879 (June 30, 2023 - \$859), of which \$679 699 is not in use. The Company has recognized \$15 30 in depreciation expense, respectively, for each of the three six months ended September 30, 2023 December 31, 2023, and 2022, on equipment in use.

#### 6 Related party transactions

One of On November 20, 2023, Dr. Brown was terminated from his position as the Company's officers Chief Scientific Officer as a result of cost-cutting measures adopted by the Company; he remains a consultant to the Company. Dr. Brown is a principal of Valent Technologies, LLC ("Valent") and as a result Valent is a related party to the Company.

On September 12, 2010, the Company entered into a Patent Assignment Agreement (the "Valent Assignment Agreement") with Valent pursuant to which Valent transferred to the Company all its right, title and interest in, and to, the patents for VAL-083 owned by Valent. The Company now owns all rights and title to VAL-083 and is responsible for further development and commercialization. In accordance with the terms of the Valent Assignment Agreement, Valent is entitled to receive a future royalty on all revenues derived from the development and commercialization of VAL-083. In the event that the Company terminates the agreement, the Company may be entitled to receive royalties from Valent's subsequent development of VAL-083 depending on the development milestones the Company has achieved prior to the termination of the Valent Assignment Agreement.

On September 30, 2014, the Company entered into an exchange agreement (the "Valent Exchange Agreement") with Valent and Del Mar (BC). Pursuant to the Valent Exchange Agreement, Valent exchanged its loan payable in the outstanding amount of \$279 (including aggregate accrued interest to September 30, 2014, of \$29), issued to Valent by Del Mar (BC), for 279 shares of the Company's Series A Preferred Stock. The Series A Preferred Stock has a stated value of \$1.00 per share (the "Series A Stated Value") and is not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3% of the Series A Stated Value per year, payable quarterly in arrears. For the three and six months ended September 30, 2023 December 31, 2023, and 2022, respectively, the Company recorded \$2 (2022 - \$2) and \$4 (2022 - \$4), respectively, related to the dividend dividends paid to Valent. The dividends have been recorded as a direct increase in accumulated deficit.

#### Related party payables

As of September 30, 2023 December 31, 2023, there is an aggregate amount of \$338 148 (June 30, 2023 - \$298) payable to the Company's officers and directors for fees, expenses, and accrued bonuses and other liabilities.

## 7 Stockholders' equity

### Preferred stock

#### Series C Preferred Stock

	Series C Preferred Stock		Series C Preferred Stock	
	Number of shares	\$ (in thousands)	Number of shares	\$ (in thousands)
Balance – June 30, 2023	14,208	10,366	14,208	10,366
Conversion of Series C Preferred stock to common stock	(50)	(37)	(540)	(393)
Balance – September 30, 2023	14,158	10,329		
Balance – December 31, 2023			13,668	9,973

In August 2020, the Company issued 25,028 shares of Series C Convertible Preferred Stock (the "Series C Preferred Stock") in three separate closings of a private placement (Series C-1, C-2, and C-3). Each share of Series C Preferred Stock was issued at a purchase price of \$1,000 per share and is convertible into shares of common stock based on the respective conversion prices which were

determined at the closing of each round of the private placement. The conversion prices for the Series C-1 Preferred Stock, Series C-2 Preferred Stock, and the Series C-3 Preferred Stock are \$58.00, \$60.70, and \$57.50, respectively. Subject to ownership limitations, the owners of the Series C-1 Preferred Stock, the Series C-2 Preferred Stock, and the Series C-3 Preferred Stock are entitled to receive dividends, payable in shares of common stock at a rate of 10%, 15%, 20% and 25%, respectively, of the number of shares of common stock issuable upon conversion of the Series C Preferred Stock, on the 12th, 24th, 36th and 48th month, anniversary of the initial closing of the private placement. The Company paid the 12th, 24th, and 36th month anniversary dividends of 10%, 15%, and 20% common stock dividends on August 19, 2021, 2022, and 2023, respectively.

The Series C Preferred Stock dividends do not require declaration by the board of directors and are accrued annually as of the date the dividend is earned in an amount equal to the fair value of the Company's common stock on the dates the respective dividends are paid. The fair value of the Series C Preferred Stock dividend paid on August 19, 2023, was determined by multiplying the

10

dividends paid of 49 shares of common stock by the Company's closing share price on August 18, 2023, of \$3.53 per share for a total

10

fair value of \$173. Any outstanding shares of Series C Preferred Stock will automatically convert to shares of common stock on August 19, 2024. In addition, as part of the Series C Preferred financing, the Company issued warrants to the placement agent ("Series C Agent Warrants").

The Series C Preferred Stock shall with respect to distributions of assets and rights upon the occurrence of a liquidation, rank (i) senior to the Company's common stock and (ii) senior to any other class or series of capital stock of the Company hereafter created which does not expressly rank pari passu with, or senior to, the Series C Preferred Stock. The Series C Preferred Stock is pari passu in liquidation to the Company's Series A Preferred Stock. The liquidation value of the Series C Preferred Stock at September 30, 2023 December 31, 2023, is the stated value of \$10,329 9,973 (June 30, 2023 - \$10,366).

The Company's Series C Preferred Stock outstanding, conversion shares, and aggregate dividends as of September 30, 2023 December 31, 2023, are as follows:

Series	Number of conversion on shares (in thousands)				Number of conversion shares (in thousands)			
	Conversion price \$	Number	Dividend Shares (in thousands)		Conversion price \$	Number	Dividend Shares (in thousands)	

Series	11,4								
1	15	58.00	197	153	10,925	58.00	188		151
Series									
2	898	60.70	15	10	898	60.70	15		10
Series	1,84								
3	5	57.50	32	25	1,845	57.50	32		24
	14,1								
	58		244	188	13,668		235		185

Series C Dividends	Dividend Shares (in thousands)
10% - August 19, 2021 (actual)	34
15% - August 19, 2022 (actual)	43
20% - August 19, 2023 (actual)	49
25% - August 19, 2024 (estimated)	62 59
	188 185

#### Series A Preferred Stock

Effective September 30, 2014, the Company filed a Certificate of Designation of Series A Preferred Stock (the "Series A Certificate of Designation") with the Secretary of State of Nevada. Pursuant to the Series A Certificate of Designation, the Company designated 279 shares of preferred stock as Series A Preferred Stock. The shares of Series A Preferred Stock have a stated value of \$1.00 per share (the "Series A Stated Value") and are not convertible into common stock. The holder of the Series A Preferred Stock is entitled to dividends at the rate of 3% of the Series A Stated Value per year, payable quarterly in arrears. Upon any liquidation of the Company, the holder of the Series A Preferred Stock will be entitled to be paid, out of any assets of the Company available for distribution to stockholders, the Series A Stated Value of the shares of Series A Preferred Stock held by such holder, plus any accrued but unpaid dividends thereon, prior to any payments being made with respect to the common stock. The Series A Preferred Stock is held by Valent (note 6).

The Series A Preferred Stock shall with respect to distributions of assets and rights upon the occurrence of a liquidation, rank (i) senior to the Company's common stock, and (ii) senior to any other class or series of capital stock of the Company hereafter created which does not expressly rank pari passu with, or senior to, the Series A Preferred Stock. The Series A Preferred Stock is pari passu in liquidation to the Company's Series C Preferred Stock. The liquidation value of the Series A Preferred stock at September 30, 2023 December 31, 2023, is its stated value of \$279 (June 30, 2023 - \$279).

There was no change to the Series A Preferred stock for the three six months ended September 30, 2023 December 31, 2023, or 2022.

#### **Common stock**

Common stock issuances during the three six months ended September 30, 2023 December 31, 2023

On September 19, 2023, the Company entered into a Sales Agreement, (the "Sales Agreement") with A.G.P./Alliance Global Partners (the "Agent") pursuant to which the Company may offer and sell, from time to time, through the Agent, as sales agent and/or

principal, shares of common stock having an aggregate offering price of up to \$2.85 million (the “ATM Facility”), subsequently increased to \$10.9 million on December 18, 2023. From October 31, 2023, until December 31, 2023, the Company raised \$2,579 in net

11

proceeds, after deducting share issuance costs of \$97, from the sale of 8,013 shares of its common stock at a weighted average price of \$0.33 per share under the ATM Facility. As of December 31, 2023, the Company has collected net proceeds of \$2.5 million for the issuance of 7,430 shares of common stock and the remaining \$103 million of net proceeds for the issuance of 581 shares of common stock are recorded as subscriptions receivable.

During the three six months ended September 30, 2023 December 31, 2023, the Company sold 400 shares of common stock at a weighted average price of \$0.23 per share for total net proceeds of approximately \$105 under the Purchase Agreement with Lincoln Park.

During the six months ended December 31, 2023, the Company issued 4 shares of common stock on vesting of restricted stock units during the period.

Common stock issuances during the three six months ended September 30, 2022

11

## December 31, 2022

On August 2, 2022, the Company entered into a stock purchase agreement, dated as of August 2, 2022, (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park committed to purchase up to a maximum of \$20,000 of shares of the Company’s common stock (the “Purchase Shares”). Concurrently with entering into the Purchase Agreement, the Company also entered into a registration rights agreement with Lincoln Park, pursuant to which it agreed to take certain actions relating to the registration of the offer and sale of the Purchase Shares available for issuance under the Purchase Agreement. Upon execution of the Purchase Agreement, the Company issued 33 shares of common stock to Lincoln Park as a commitment fee in connection with entering into the Purchase Agreement.

Pursuant to the Purchase Agreement, the Company has the right, in its sole discretion, to present Lincoln Park with a purchase notice directing Lincoln Park to purchase up to 10 Purchase Shares provided that the closing sale price of the common stock on the purchase date is not below a threshold price set forth in the Purchase Agreement (a “Regular Purchase”). The Company and Lincoln Park may mutually agree to increase the Regular Purchase amount with respect to any Regular Purchase under the Purchase Agreement, provided that Lincoln Park’s maximum committed purchase obligation under any single Regular Purchase shall not exceed \$2,000. The purchase price per share for each Regular Purchase is based on prevailing market prices of the common stock immediately preceding the time of sale as computed in accordance with the terms set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park must pay for the Purchase Shares under the Purchase Agreement.

If the Company directs Lincoln Park to purchase the maximum number of shares of common stock that the Company may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the Purchase Agreement, the Company may direct Lincoln Park to purchase additional shares of common stock in an “accelerated purchase” (each, an “Accelerated Purchase”) and an “additional accelerated purchase” (each, an “Additional Accelerated Purchase”) (including multiple

Additional Accelerated Purchases on the same trading day) as provided in the Purchase Agreement. The purchase price per share for each Accelerated Purchase and Additional Accelerated Purchase will be based on market prices of the common stock on the applicable purchase date for such Accelerated Purchases and such Additional Accelerated Purchases.

Subsequent to September 30, 2023 During the six months ended December 31, 2023, the Company received stockholder approval to issue 20% or more of its outstanding shares as of the date the Company entered into the Purchase Agreement with Lincoln Park. The Purchase Agreement may be terminated by the Company at any time, at its sole discretion, without any cost or penalty, by giving one business day notice to Lincoln Park to terminate the Purchase Agreement.

During the three six months ended September 30, 2022 December 31, 2022, the Company sold 229 shares of common stock for total net proceeds of approximately \$1,903 under this Purchase Agreement. As of September 30, 2023, the sales made under the Purchase Agreement are the maximum amounts available due to ownership limitations under Nasdaq rules.

2017 Omnibus Incentive Plan

As subsequently approved by the Company’s stockholders at an annual meeting of stockholders, on April 11, 2018, the Company’s board of directors approved the adoption of the Company’s 2017 Omnibus Equity Incentive Plan (the “2017 Plan”), as amended. The board of directors also approved a form of Performance Stock Unit Award Agreement to be used in connection with grants of performance stock units (“PSUs”) as well as a Restricted Stock Unit (“RSU”) award under the 2017 Plan. As approved by the Company’s stockholders on June 21, 2022, the number of common shares available under the 2017 Plan as of September 30, 2023 December 31, 2023, is 440 shares, less the number of shares of common stock issued under the Del Mar (BC) 2013 Amended and Restated Stock Option Plan (the “Legacy Plan”), or that are subject to grants of stock options made, or that may be made, under the Legacy Plan, or that have been previously exercised.

The following table sets forth the aggregate information on all equity compensation plans as of September 30, 2023 December 31, 2023:

	Number of shares of common stock to be issued upon exercise of outstanding stock options and rights (a)	Weighted-average exercise price of stock options and rights \$	Number of shares of common stock remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))(2)
Plan (in thousands, except per share amounts)			
Equity compensation plans approved by security holders - 2017 Plan(1)	274	19.18	87

Equity compensation plans not approved by security holders - Del Mar (BC) 2013 Amended and Restated Stock Option Plan	1	2,207.18	—
<b>Totals</b>	<b>275</b>	<b>33.76</b>	<b>87</b>
<div> <div>Number of shares of common stock to be issued upon exercise of outstanding stock options and rights</div> <div>Weighted-average exercise price of stock options and rights</div> <div>Number of shares of common stock remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))<sup>(2)</sup></div> </div>			
<b>Plan (in thousands, except per share amounts)</b>	<b>(a)</b>	<b>\$</b>	<b>(a))<sup>(2)</sup></b>
Equity compensation plans approved by security holders - 2017 Plan <sup>(1)</sup>	236	21.16	129
Equity compensation plans not approved by security holders - Del Mar (BC) 2013 Amended and Restated Stock Option Plan	1	2,175.08	—
<b>Totals</b>	<b>237</b>	<b>32.92</b>	<b>129</b>

<sup>(1)</sup> The Del Mar (BC) 2013 Amended and Restated Stock Option Plan refers to the Company's previous equity compensation plan.

<sup>(2)</sup> The balance of 91 shares of common stock available for issuance under the 2017 Plan as of **September 30, 2023** **December 31, 2023**, is net of stock options previously exercised.

The maximum number of shares of Company common stock with respect to which any one participant may be granted awards during any calendar year is 8% of the Company's fully diluted shares of common stock on the date of grant (excluding the number of shares of common stock issued under the 2017 Plan and/or the Legacy Plan or subject to outstanding awards granted under the 2017 Plan and/or the Legacy Plan). No award will be granted under the 2017 Plan on, or after, July 7, 2027.

### Stock options

During the **three six** months ended **September 30, 2023** **December 31, 2023**, a total of 89 stock options to purchase shares of common stock at an exercise price of \$4.655 **per share** were granted to directors and officers of the Company. The 26 options granted to non-employee directors vest pro rata monthly over 12 months commencing on **September 30, 2023** **December 31, 2023**. The remaining 63 options granted to executive officers, employees and consultants vest as to 25% on the first anniversary of grant with the remaining portion vesting pro rata monthly thereafter over 36 months. All of the options to purchase shares of common stock granted have a 10-year term and are subject to cancellation upon the grantees' termination of service for the Company, with certain exceptions.

The following table sets forth changes in stock options outstanding under all plans:

	Number of stock options outstanding (in thousands)	Weighted average exercise price	Number of stock options outstanding (in thousands)	Weighted average exercise price
<b>Balance – June 30, 2023</b>	198	51.71	198	51.71
Granted	89	4.66	89	4.66



Expired	(1)	2,100.00	(19)	140.20
Forfeited	(11)	11.10	(31)	8.26
<b>Balance – September 30, 2023</b>	<u>275</u>	<u>33.76</u>		
<b>Balance – December 31, 2023</b>			<u>237</u>	<u>32.92</u>

The following table summarizes stock options outstanding and exercisable under all plans at **September 30, 2023** **December 31, 2023**:

Exercise price \$	Number Outstanding at September 30, 2023 (in thousands)	Weighted average remaining contractual life (years)	Number exercisable at September 30, 2023 (in thousands)			
				Number Outstanding at December 31, 2023 (in thousands)	Weighted average remaining contractual life (years)	Number exercisable at December 31, 2023 (in thousands)
4.66	89	9.92	2	79	9.67	8
6.04	9	9.39	—	9	9.14	—
8.79	52	8.25	17	39	7.63	16
12.75 to 16.25	6	9.04	6	6	8.78	6
30.50 to 48.00	83	7.61	44	80	7.14	47
62.00 to 68.50	14	7.62	14	14	6.81	14
85.00	21	3.07	21	9	5.43	9
1,055.00 to 2,660.00	1	1.97	1			
304.95 to 2,660.00				1	2.33	1
	<u>275</u>		<u>105</u>	<u>237</u>		<u>101</u>

Stock options granted during the **three** **six** months ended **September 30, 2023** **December 31, 2023**, have been valued using a Black-Scholes pricing model with the following assumptions:

	<b>September 30, December 31, 2023</b>
Dividend rate	— %
Estimated volatility	91.40 %
Risk-free interest rate	4.24 %
Expected term – years	6.08

The estimated volatility of the Company's common stock at the date of issuance of the stock options is based on the historical volatility of the Company. The risk-free interest rate is based on rates published by the government for bonds with a maturity similar to the expected remaining term of the stock options at the valuation date. The expected term of the stock options has been estimated using the plain vanilla method.

The Company has recognized the following amounts as stock option expense for the periods noted (in thousands):

	<b>Three months ended</b>		<b>Three months ended</b>		<b>Six months ended</b>	
	<b>September 30,</b>		<b>December 31,</b>		<b>December 31,</b>	
	<b>2023</b>	<b>2022</b>	<b>2023</b>	<b>2022</b>	<b>2023</b>	<b>2022</b>
	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>	<b>\$</b>
Research and development	69	140	24	134	93	274
General and administrative	91	378	141	302	232	680
	160	518	165	436	325	954

All of the stock option expense for the periods ended **September 30, 2023** **December 31, 2023**, and 2022, has been recognized as additional paid in capital. The aggregate intrinsic value of stock options outstanding as well as stock options exercisable was nil as of **September 30, 2023** **December 31, 2023**, and 2022, respectively. As of **September 30, 2023** **December 31, 2023**, there was \$**870** **603** in unrecognized compensation expense that will be recognized over the next **2.58** **2.36** years.

The following table sets forth changes in unvested stock options under all plans:

	<b>Number of</b>	<b>Weighted</b>		<b>Number of</b>	<b>Weighted</b>
	<b>Options</b>	<b>average</b>		<b>Options</b>	<b>average</b>
	<b>(in thousands)</b>	<b>exercise</b>		<b>(in thousands)</b>	<b>exercise</b>
		<b>price</b>			<b>price</b>
		<b>\$</b>			<b>\$</b>
<b>Unvested at June 30, 2023</b>	118	24.12		118	24.12
Granted	89	4.66		89	4.66
Vested	(26)	19.50		(40)	19.68
Forfeited	(11)	11.10		(31)	8.26
<b>Unvested at September 30, 2023</b>	170	15.49			

Unvested at December 31, 2023	136	16.33
-------------------------------	-----	-------

The aggregate intrinsic value of unvested stock options at September 30, 2023 December 31, 2023, was nil (2022 - nil). The unvested stock options have a remaining weighted average contractual term of 9.26 9.00 years (2022 – 9.37 9.18).

### Restricted stock units

During the three six months ended September 30, 2023 December 31, 2023, the Company recognized a total of \$47 85 (2022 - nil) in compensation expense related to RSUs.

	Number of RSU (in thousands)
Balance – June 30, 2023	78
Issuance of restricted stock units	—
Vesting of restricted stock units	(4)
Forfeiture of restricted stock units	(58)
Balance – September 30, 2023 December 31, 2023	69 66

14

### Common stock warrants

The following table sets forth changes in outstanding common stock warrants:

	Number of Warrants (in thousands)	Weighted average exercise price \$	Number of Warrants (in thousands)	Weighted average exercise price \$
Balance – June 30, 2023	713	43.55	713	43.55
Expiry of warrants issued for services	(7)	87.69	(13)	89.80
Balance – September 30, 2023	706	43.12		
Balance – December 31, 2023			700	43.12

The following table summarizes the Company's outstanding common stock warrants as of **September 30, 2023** **December 31, 2023**:

Description of warrants	Number (in thousands)	Exercise price \$	Expiry date	Number (in thousands)	Exercise price \$	Expiry date
2022 April Investor warrants	325	20.50	April 14, 2027	325	20.50	April 14, 2027
2022 Investor warrants	240	62.50	March 28, 2025	240	62.50	March 28, 2025
2020 Investor warrants	65	50.00	August 16, 2024	65	50.00	August 16, 2024
2019 Investor warrants	15	155.00	June 5, 2024	15	155.00	June 5, 2024
NBTS Warrants	3	54.50	June 19, 2025	3	54.50	June 19, 2025
Warrants issued for services	13	32.00 to 450.00	October 11, 2023 to February 25, 2024	7	32.00 to 137.50	January 7, 2024 to February 25, 2024
2022 April Agent warrants	32	33.12	October 14, 2026	32	33.12	October 14, 2026
2022 Agent warrants	12	78.12	March 28, 2025	12	78.12	March 28, 2025
2019 Agent warrants	1	193.75	June 3, 2024	1	193.75	June 3, 2024
	<u>706</u>			<u>700</u>		

### Series C Preferred Stock warrants

In connection with the Series C Preferred Stock private placement, the Company issued 2,504 Series C Agent Warrants. The Series C Agent Warrants have an exercise price of \$1,000 per share, provide for a cashless exercise feature, and are exercisable for a period of four years from August 19, 2020. The Series C Preferred Stock issuable upon exercise of the Series C Agent Warrants is convertible into shares of common stock in the same manner as each respective underlying series of outstanding Series C Preferred Stock and will be entitled to the same dividend rights as each respective series.

The following table sets forth changes in outstanding Series C Agent Warrants:

	Balance June 30, 2023	Number of Warrants Issued	Number of Warrants Exercise d	Balance, September 30, 2023	Conversion price \$	Balance June 30, 2023	Number of Warrants Issued	Number of Warrants Exercised	Balance, December 31, 2023	Conversion price \$
Preferred Series C-1 Agent Warrants	1,929	—	—	1,929	58.00	1,929	—	—	1,929	58.00
Preferred Series C-2 Agent Warrants	219	—	—	219	60.70	219	—	—	219	60.70
Preferred Series C-3 Agent Warrants	296	—	—	296	57.50	296	—	—	296	57.50
	2,444	—	—	2,444		2,444	—	—	2,444	

The following table summarizes the Company's outstanding Series C Agent Warrants as of **September 30, 2023** **December 31, 2023**:

Series C Agent Warrants	Number	Conversion price \$	Number of conversion shares (in thousands)	Cumulative common stock dividends (in thousands)
Series 1	1,929	58.00	33	23
Series 2	219	60.70	4	3
Series 3	296	57.50	5	4
	2,444		42	30

## 8 Supplementary statement of cash flows information

The Company incurred the following non-cash investing and financing transactions (in thousands):

	Three months ended		Six months ended	
	September 30,		December 31,	
	2023	2022	2023	2022
	\$	\$	\$	\$
Series C Preferred Stock common stock dividend (note 7)	173	362	173	362
Non-cash issue costs (note 7)	—	289	—	289
Issue costs in accounts payable and accrued liabilities	—	48		
Subscriptions receivable (note 7)			103	—
Equipment additions reclassified from prepaid expenses	—	447	—	447
Income taxes paid	—	—	—	—
Interest paid	—	—	—	—

## 9 Financial instruments

The Company's financial instruments are measured at fair value as determined by using the fair value hierarchy for inputs that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use to value an asset or liability and are developed based on market data obtained from independent sources. Unobservable inputs are inputs based on assumptions about the factors market participants would use to value an asset or liability. The three levels of inputs that may be used to measure fair value are as follows:

- ☐ Level one - inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities;
- ☐ Level two - inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals; and
- ☐ Level three - unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.

Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. Changes in the observability of valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. As of **September 30, 2023** **December 31, 2023**, the Company's milestone payment liability was measured using level 3 inputs. The milestone payment liability relates to contingent milestone payments for the REM-001 program that was acquired in the Adgero merger (note 1).

	September 30, December 31, 2023		
Liability	Level 1	Level 2	Level 3
Milestone payment liability	—	—	167 179
		\$	
		(in thousands)	
Balance – June 30, 2023			166
Change in fair value estimate			13

The Company's financial instruments consist of cash and cash equivalents, other receivables, accounts payable, and related party payables. The carrying values of cash and cash equivalents, other receivables, accounts payable and related party payables approximate their fair values due to the immediate or short-term maturity of these financial instruments.

## 10 Subsequent events

The Company has evaluated its subsequent events from September 30, 2023 December 31, 2023, through the date these condensed consolidated interim financial statements were issued and has determined that there are no subsequent events requiring disclosure in these condensed consolidated interim financial statements other than the items noted below.

### Clinical trial deposit

In October 2023, the Company received \$234 as a return of clinical trial deposit from a clinical research organization in connection with the REM-001 15-patient clinical study.

### Clinical trial results for VAL-083 – suspension of VAL-083 development

On October 31, 2023, the Company announced preliminary topline results for VAL-083 from the Glioblastoma Adaptive Global Innovative (“GBM AGILE”) study. VAL-083 did not perform better than the current standards of care in glioblastoma and the preliminary safety data was similar to that of the current standards of care used to treat glioblastoma. As a result, the Company announced that it is suspending the development of VAL-083 and turning its focus to its REM-001 program.

### Proceeds from the Company's At-The-Market (“ATM”) facility

16

On September 19, 2023, the Company entered into a Sales Agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Agent”) pursuant to which the Company may offer and sell, from time to time, through the Agent, as sales agent and/or principal, shares of common stock having an aggregate offering price of up to \$2.85 million (the “ATM Facility”). From October 31, 2023 January 1, 2024 until November 13, 2023 February 12, 2024, the Company raised \$968 6,108 in net proceeds from the sale of 1,629 28,870 shares of its common stock under the ATM Facility.

Lincoln Park Purchase Agreement 16

### Final CRO payment

On October 9, 2023 January 9, 2024, the Company received stockholder approval paid \$400 pursuant to issue the termination agreement with the CRO (Note 3).

### Initiation of REM-001 Clinical Study

On February 12, 2024, the Company announced the initiation of a REM-001 15-patient clinical trial in CMBC patients.

### Opt-Out Notice to Valent for VAL-083

On February 13, 2024, the Company sent an Opt-Out Notice to Valent under the Valent Assignment Agreement whereby the Company assigned all rights, title, and interest in and to the patents for VAL-083 to Valent. As a result, the Company granted Valent a non-exclusive, fully-paid, royalty-free, perpetual, worldwide and non-transferable license, subject to limited exceptions. The Company is entitled to receive royalties from Valent's subsequent commercialization equal to 20% or more of its outstanding shares as of Valent Net Sales (as defined in the date the Company entered into the Purchase Agreement with Lincoln Park. Valent Assignment Agreement).

## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

This Management's Discussion and Analysis ("MD&A") contains "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995, which represent our projections, estimates, expectations, or beliefs concerning, among other things, financial items that relate to management's future plans or objectives or to our future economic and financial performance. In some cases, you can identify these statements by terminology such as "may," "should," "plans," "believe," "will," "anticipate," "estimate," "expect," "project," or "intend," including their opposites or similar phrases or expressions. You should be aware that these statements are projections or estimates as to future events and are subject to a number of factors that may tend to influence the accuracy of the statements. These forward-looking statements should not be regarded as a representation by us or any other person that our events or plans will be achieved. You should not unduly rely on these forward-looking statements, which speak only as of the date of this report. Except as may be required under applicable securities laws, we undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this report or to reflect the occurrence of unanticipated events.

You should review the factors and risks we describe under "Risk Factors" in our Annual Report on Form 10-K for the year ended June 30, 2023, and in our other filings with the Securities and Exchange Commission (the "SEC"), available at [www.sec.gov](http://www.sec.gov). Actual results may differ materially from any forward-looking statement.

All amounts are expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted.

### Background

Kintara Therapeutics, Inc. is a clinical stage, biopharmaceutical company focused on the development and commercialization of new cancer therapies. On August 19, 2020, the Company completed its merger with Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation ("Adgero") in which Adgero continued its existence under Delaware law and became a direct, wholly-owned subsidiary of the Company. In connection with the Adgero merger, the Company also became the parent company of Adgero Biopharmaceuticals, Inc. ("Adgero Bio"). Following the completion of the merger, we changed our name from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc. and began trading on The Nasdaq Capital Market LLC ("Nasdaq") under the symbol "KTRA."

We are the parent company of Del Mar (BC), a British Columbia, Canada corporation, and Adgero. Adgero Biopharmaceuticals Holdings, Inc., a Delaware Corporation ("Adgero"). We are also the parent company to Callco 0959454 B.C. Ltd. ("Callco") and Exchangeco, 0959456 B.C. Ltd. ("Exchangeco"), which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition that occurred in 2013.



References to “we,” “us,” and “our,” refer to Kintara and our wholly-owned subsidiaries, Del Mar Pharmaceuticals (BC) Ltd. (“Del Mar (BC)”), Adgero, Adgero Bio, Biopharmaceuticals, Inc. (“Adgero Bio”), Callico, and Exchangeco.

We are dedicated to the development of novel cancer therapies for patients with unmet medical needs. Our mission is to benefit patients by developing and commercializing anti-cancer therapies for patients whose solid tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, with particular focus on orphan cancer indications.

Our two lead candidates are VAL-083, a novel, validated, DNA-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma (“GBM”) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (“NSCLC”), and diffuse intrinsic pontine glioma (“DIPG”), and candidate is REM-001, a late-stage photodynamic therapy (“PDT”) for the treatment of cutaneous metastatic breast cancer (“CMBC”). PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of reactive oxygen that induces local tumor cell death.

## Recent Events

- Effective July 1, 2023, we were awarded a \$2.0 million grant from the National Institutes of Health (“NIH”) to be received over a year period as expenses are incurred. The grant from the NIH will fund the majority of expenses related to the REM-001 CMBC patient clinical study.
- On September 20, 2023, the Nasdaq Staff notified us that we did not comply with the Stockholders’ Equity Requirement (the “Notice”). Pursuant to the Notice, we submitted a plan to regain compliance and received an extension of 180 calendar days from the date of the Notice, or March 18, 2024, to evidence compliance and to maintain compliance through December 31, 2024. The Notice has no immediate effect on the listing of our common stock and our common stock continues to trade on The Nasdaq Capital Market under the symbol “KTRA,” subject to our compliance with the other continued listing requirements.
- On October 31, 2023, we announced preliminary topline results for VAL-083, a DNA-targeting agent intended to treat drug-resistant solid tumors such as glioblastoma (“GBM”) and potentially other smaller tumors, from the Glioblastoma Adaptive Global Innovative Learning Environment (“GBM AGILE”) study. VAL-083 did not perform better than the current standards of care in glioblastoma. The preliminary safety data was similar to that of the current standards of care used to treat glioblastoma. As a result, we announced that we are suspending/terminated the development of VAL-083 and turning/have turned our focus to our REM-001 program.

18

- On December 13, 2023, the Nasdaq staff notified us that we did not comply with the Minimum Bid Price Requirement (the “Bid Price Notice”). Pursuant to the Bid Price Notice, we have 180 calendar days from the date of the Bid Price Notice, or June 10, 2024, to regain compliance for a minimum of ten consecutive business days.
- In December 2023, we announced that our Board of Directors has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value.
- On February 12, 2024, we announced the initiation of an open label 15-patient study in CMBC patients which is evaluating REM-001 (the “REM-001 Study”), a second-generation PDT photosensitizer agent, and is designed to test the 0.8 mg dose as well as optimize the study design in advance of a Phase 3 trial initiation. The primary endpoint in the study is Best Overall Objective Response Rate (“bORR”) (complete response or partial response) of the target treatment fields at any time from treatment up to and including, week 24. The majority of the costs to run this study will be covered by the \$2.0 million Small Business Innovation Research grant Kintara was awarded from the NIH.

## Upcoming Clinical Milestones

As a result of receiving the NIH grant, we restarted re-initiated our REM-001 program and we expect to start enrolling patients in the REM-001 CMBC 15-patient clinical study Study in the fourth first quarter of calendar year 2023, 2024.

### REM-001

#### Background

Through REM-001, we are developing our photodynamic therapy ("PDT") for the treatment of rare, unmet medical needs. PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as catalysts to produce a form of oxygen that induces local tumor cell death. REM-001 consists of three parts: the laser light source, the light delivery device, and the REM-001 drug product (collectively, the "REM-001 Therapy"). REM-001 consists of an active pharmaceutical ingredient ("API") in a lipid formulation. The REM-001 API is SnET2 ("tin ethyl etiopurpurin") which is a second-generation PDT photosensitizer agent. We believe REM-001 possesses multiple advantages over earlier generation PDT compounds.

Our lead indication for REM-001 is CMBC which is a disease that may strike individuals with advanced breast cancer and for which effective treatment options are limited. In four Phase 2 and/or Phase 3 clinical studies in CMBC patients, primarily targeting patients who had previously received chemotherapy and failed radiation therapy, REM-001 Therapy was able to reduce, or eliminate, a substantial number of the treated CMBC tumors. Specifically, our analysis of the data collected from these studies indicates that in approximately 80% of evaluable tumor sites treated with REM-001 Therapy, there was a complete response; meaning that follow-up clinical assessments indicated no visible evidence of the tumor remaining. We believe clinical data indicates that REM-001 Therapy holds promise as a treatment to locally eliminate, or slow the growth of, treated cutaneous cancerous tumors in this difficult-to-treat patient population.

Numerous approaches have been utilized to treat CMBC patients, including various forms of chemotherapy, radiation therapy, surgical excision, hyperthermia, cryotherapy, electro-chemotherapy, topical drugs, and intra-lesional chemotherapy injections. However, for the most part, we believe that these therapies are often inadequate given the limited efficacy, toxicities and/or side effects of each. We believe our REM-001 Therapy has several advantages for this indication: it can be highly directed to the tumor site, has minimal systemic effects or normal tissue toxicities, can be used in conjunction with other therapies, and can be periodically repeated.

Our REM-001 Therapy product consists of three parts: the DD series laser light source (or equivalent), the ML2-0400 light delivery device (or equivalent) and the drug REM-001. In use, REM-001 is first administered by intravenous infusion and allowed to distribute within the body and be taken up by the tumors. Tumors are then illuminated with light using the light delivery device, which is attached to the laser light source, so that the accumulated REM-001 can be activated for the desired clinical effect.

As a result of our review of the historical data, we submitted questions to the FDA U.S. Food and Drug Administration ("FDA") under a Type C format to review the technology and results and determine the anticipated requirements for regulatory approval. On March 3, 2017, we received the FDA's written response to these questions. Based on that response, we have successfully manufactured REM-001 and developed light delivery devices for our planned 15-patient Phase 2 study. We received a Study May Proceed letter from the FDA for our 15-patient study on August 9, 2022.

On October 19, 2022, we announced that the REM-001 program in CMBC was paused to conserve cash which will be used to support the funding of the GBM AGILE Study. Effective July 1, 2023, the Company was awarded a two-year \$2,000 Small Business Innovation Research grant from the National Institutes of Health to support the clinical development of REM-001 for the treatment of CMBC. The grant will be received in tranches of approximately \$1,250 for the period July 1, 2023, to June 30, 2024, and approximately \$750 for the period July 1, 2024, to June 30, 2025. As a result of receiving the grant, we are in the process of re-initiating have re-initiated the REM-001 program and we expect to start enrolling patients in the fourth REM-001 Study in the first quarter of calendar year 2023, 2024.

## REM-001 Regulatory Filings

On August 9, 2022, we announced that we received a Study May Proceed letter from the FDA to begin our 15-patient study evaluating REM-001 PDT for the treatment of CMBC. The FDA has granted us **FTD Fast Track Designation ("FTD")** for REM-001 in CMBC.

## VAL-083

On October 31, 2023, we announced preliminary topline results for VAL-083 from the **Glioblastoma Adaptive Global Innovative Learning Environment ("GBM AGILE") AGILE** study. VAL-083 did not perform better than the current standards of care in glioblastoma and the preliminary safety data was similar to that of the current standards of care used to treat glioblastoma. As a result, we **announced that we are suspending terminated** the development of **VAL-083 VAL-083**. On February 13, 2024, we sent an Opt-Out Notice to Valent under the Valent Assignment Agreement whereby we assigned all rights, title, and **turning our focus interest in and to** our REM-001 program. We expect to have the full dataset from the GBM AGILE study around the end of the first quarter of calendar year 2024 to better understand if there are possible pathways for further development of VAL-083.

## Background

VAL-083 is a first-in-class, small-molecule, DNA-targeting chemotherapeutic that has demonstrated activity against a range of tumor types in prior human Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute ("NCI"). "First-in-class" means that VAL-083 embodies a unique molecular structure which is not an analogue, or derivative, of any approved product, or product under development, for the treatment of cancer. As part of our business strategy, we leverage and build upon these prior NCI investments and data from more than 40 NCI Phase 1 and Phase 2 clinical studies, which includes an approximately 1,200 patient safety database.

We recently announced preliminary topline data **patents** for VAL-083 **to Valent**. As a result, we granted Valent a non-exclusive, fully-paid, royalty-free, perpetual, worldwide and non-transferable license, subject to limited exceptions. We are entitled to receive royalties from the GBM AGILE Study. The GBM AGILE Study is an international, innovative platform study designed to more rapidly identify and confirm effective therapies for patients with newly-diagnosed and recurrent GBM through responsive adaptive randomization and a seamless Phase 2/3 clinical design. Patients in the GBM AGILE Study were tested for their O<sup>6</sup>-methyl guanine methyltransferase ("MGMT") methylation status prior to enrollment. VAL-083 was being evaluated in all three GBM patient subtypes in this study: newly-diagnosed methylated MGMT; newly-diagnosed unmethylated MGMT; and recurrent.

We have also completed two open-label, biomarker-driven, Phase 2 studies in MGMT-unmethylated GBM. MGMT is a DNA-repair enzyme that is associated with resistance to temozolomide ("TMZ" or Temodar®), the current standard-of-care chemotherapy used in the treatment of GBM. More than 60% of GBM patients have MGMT-unmethylated tumors and exhibit a high expression of MGMT which is correlated with TMZ resistance, treatment failure, and poor patient outcomes as indicated in the current National Comprehensive Cancer Network ("NCCN") guidelines for GBM treatment. Our research demonstrates that VAL-083's anti-tumor activity is independent of MGMT

expression. In our completed Phase 2 studies, we used MGMT as a biomarker to identify patients for treatment with VAL-083 in three distinct GBM unmethylated MGMT patient populations: newly-diagnosed first line, newly-diagnosed adjuvant, and recurrent.

VAL-083 has been designated by the U.S. Food and Drug Administration ("FDA") as an orphan drug under the Orphan Drug Act and the European Medicines Agency ("EMA") for the treatment of gliomas, including GBM. The FDA has also granted Orphan Drug designation to VAL-083 for the treatment of medulloblastoma, DIPG, and ovarian cancer. The FDA has granted us Fast Track Designation ("FTD") for VAL-083 in newly-diagnosed MGMT-unmethylated and recurrent GBM.

We have a broad patent portfolio to protect our intellectual property. Our patents and patent applications claim methods of use of VAL-083 and related compounds, synthetic methods, and quality controls for the manufacturing process of VAL-083. We believe that our portfolio of intellectual property rights provides a defensible market position for the Valent's subsequent commercialization of VAL-083 equal to 5% of Valent Net Sales (as defined in the United States and other international markets, Valent Assignment Agreement).

## Corporate History

We are a Nevada corporation formed on June 24, 2009, under the name Berry Only Inc. On January 25, 2013, we entered into and closed an exchange agreement (the "Exchange Agreement"), with Del Mar Pharmaceuticals (BC) Ltd. ("Del Mar (BC)"), 0959454 B.C. Ltd. ("Calco"), Calco, and 0959456 B.C. Ltd. ("Exchangeco") Exchangeco and the security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del Mar (BC) became a wholly-owned subsidiary of ours (the "Reverse Acquisition").

On August 19, 2020, we acquired Adgero and changed our name from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc. We are the parent company to the following entities:

- Del Mar (BC), a British Columbia, Canada corporation incorporated on April 6, 2010, which is a clinical stage company with a focus on the development of drugs for the treatment of cancer;
- Adgero, a Delaware corporation incorporated on October 26, 2015, which is a clinical stage company with a focus on the development of photodynamic therapy for the treatment of rare, unmet medical needs, specifically orphan cancer indications;
- Adgero Biopharmaceuticals, Inc. a Delaware corporation incorporated on November 16, 2007; and
- Calco and Exchangeco which are British Columbia, Canada corporations. Calco and Exchangeco were formed to facilitate the Reverse Acquisition.

## Outstanding Securities

As of November 13, 2023 February 12, 2024, we had 3,387,808 39,038 shares of common stock issued and outstanding, outstanding warrants to purchase 706 700 shares of common stock, warrants to purchase 2,444 shares of our Series C Preferred Stock that upon exercise are convertible into 42 shares of common stock, outstanding stock options to purchase 275 237 shares of common stock, 69 66 restricted stock units, and 14,008 13,668 outstanding shares Series C Preferred Stock that are convertible into 241 235 shares of common stock. All common stock warrants, stock options, and restricted stock units are convertible, or exercisable into, one share of common stock. The Series C Preferred Stock

20

(issued (issued in three series) is convertible into shares of common stock at \$58.00 per share (Series C-1), \$60.70 per share (Series C-2) or \$57.50 per share (Series C-3), respectively. The Series C Preferred stock purchase warrants are convertible into Series C Preferred Stock at \$1,000 per share for either Series C-1, Series C-2, or Series C-3 Preferred Stock, as applicable.

## Selected Quarterly Information

The financial information reported herein has been prepared in accordance with accounting principles generally accepted in the United States. Our functional currency at **September 30, 2023** **December 31, 2023**, and June 30, 2023, is the US\$. The following tables represent selected financial information for us for the periods presented. All amounts in the remainder of this MD&A are expressed in thousands, except par value and per share amounts, unless otherwise noted.

20

### Selected Balance Sheet Data

	September 30, 2023 \$	June 30, 2023 \$	December 31, 2023 \$	June 30, 2023 \$
	(in thousands)		(in thousands)	
Cash and cash equivalents	216	1,535	658	1,535
Working capital	(2,553)	188	(684)	188
Total assets	1,477	3,979	1,885	3,979
Total stockholders' equity (deficiency)	(2,026)	731		
Total stockholders' equity			(164)	731

### Selected Statement of Operations Data

#### For the three months ended

	September 30, 2023 \$	September 30, 2022 \$	December 31, 2023 \$	December 31, 2022 \$
	(in thousands, except per share data)		(in thousands, except per share data)	
<b>Expenses</b>				
Research and development	1,859	3,171	111	2,059
General and administrative	1,103	1,475	908	1,440
	(2,962)	(4,646)	(1,019)	(3,499)
<b>Other income (loss)</b>				
Foreign exchange	(2)	11	(6)	—

Interest, net	2	39	2	45
	—	50	(4)	45
<b>Net loss for the period</b>	(2,962)	(4,596)	(1,023)	(3,454)
Series A Preferred cash dividend	(2)	(2)	(2)	(2)
Series C Preferred stock dividend	(173)	(362)	—	—
<b>Net loss for the period attributable to common stockholders</b>	(3,137)	(4,960)	(1,025)	(3,456)
<b>Basic and fully diluted weighted average number of shares</b>	1,718	1,464	4,337	1,643
<b>Basic and fully diluted loss per share</b>	(1.83)	(3.39)	(0.24)	(2.10)

#### For the six months ended

	December 31, 2023	December 31, 2022
	\$	\$
	(in thousands, except per share data)	
<b>Expenses</b>		
Research and development	1,970	5,230
General and administrative	2,011	2,915
	(3,981)	(8,145)
<b>Other income</b>		
Foreign exchange	(8)	11
Interest, net	4	84
	(4)	95
<b>Net loss for the period</b>	(3,985)	(8,050)
Series A Preferred cash dividend	(4)	(4)
Series C Preferred stock dividend	(173)	(362)
<b>Net loss for the period attributable to common stockholders</b>	(4,162)	(8,416)
<b>Basic and fully diluted weighted average number of shares</b>	3,027	1,554
<b>Basic and fully diluted loss per share</b>	(1.37)	(5.42)

#### Expenses, net of non-cash, share-based compensation expense – non-GAAP

The following table discloses research and development, and general and administrative expenses net of non-cash, share-based compensation payment expense. The disclosure has been provided to reconcile the total operational expenses on a GAAP basis and the

non-GAAP operational expenses net of non-cash stock-based compensation in order to provide an estimate of cash used in research and development, and general and administrative expense. Management uses the cash basis of expenses for forecasting and budget purposes to determine the allocation of resources and to plan for future financing opportunities.

21

#### For the three months ended

	September 30, 2023	September 30, 2022	December 31, 2023	December 31, 2022
	\$	\$	\$	\$
	(in thousands)	(in thousands)	(in thousands)	(in thousands)
Research and development – GAAP	1,859	3,171	111	2,059
Less: non-cash, share-based compensation expense	(86)	(140)	(23)	(134)
Research and development net of non-cash, share-based, compensation expense – Non-GAAP	1,773	3,031	88	1,925
General and administrative – GAAP	1,103	1,475	908	1,440
Less: non-cash, share-based compensation expense	(121)	(378)	(180)	(302)
General and administrative net of non-cash, share-based, compensation expense – Non-GAAP	982	1,097	728	1,138

#### For the six months ended

	December 31, 2023	December 31, 2022
	\$	\$
	(in thousands)	(in thousands)
Research and development – GAAP	1,970	5,230
Less: non-cash, share-based compensation expense	(109)	(274)
Research and development net of non-cash, share-based, compensation expense – Non-GAAP	1,861	4,956
General and administrative – GAAP	2,011	2,915
Less: non-cash, share-based compensation expense	(301)	(680)
General and administrative net of non-cash, share-based, compensation expense – Non-GAAP	1,710	2,235

#### Results of Operations

Comparison of the three months ended **September 30, 2023** December 31, 2023, and **September 30, 2022** December 31, 2022

Three months ended	Three months ended
--------------------	--------------------

	September 30, 2023	September 30, 2022	Change \$	Change %	December 31, 2023	December 31, 2022	Change \$	Change %
	\$	\$	\$	%	\$	\$	\$	%
	(in thousands)				(in thousands)			
<b>Expenses</b>								
Research and development	1,859	3,171	(1,312)	(41)	111	2,059	(1,948)	(95)
General and administrative	1,103	1,475	(372)	(25)	908	1,440	(532)	(37)
			1,68					
	(2,962)	(4,646)	4		(1,019)	(3,499)	2,480	
<b>Other income (loss)</b>								
Foreign exchange	(2)	11	(13)	(118)	(6)	—	(6)	—
Interest, net	2	39	(37)	(95)	2	45	(43)	(96)
	—	50	(50)		(4)	45	(49)	
<b>Net loss</b>			1,63					
	(2,962)	(4,596)	4		(1,023)	(3,454)	2,431	

### Research and Development

Research and development expenses decreased to \$1,859 \$111 for the three months ended September 30, 2023 December 31, 2023, from \$3,171 \$2,059 for the three months ended September 30, 2022 December 31, 2022. The decrease was largely attributable to lower clinical development costs and lower non-cash, share-based compensation expenses incurred during the three months ended September 30, 2023 December 31, 2023, compared to the three months ended September 30, 2022 December 31, 2022.

Clinical development costs have decreased in the current quarter compared to the same quarter in the prior fiscal year in part due to costs related to the GBM AGILE Study being lower in the three months ended September 30, 2023 December 31, 2023, compared to the three months ended September 30, 2022 December 31, 2022. In addition, on October 19, 2022, we announced that we had paused the REM-001 program in order to preserve cash for the development of VAL-083. On June 28, 2023, we announced the restart of the REM-001 program as a result of the awarding of a \$2 million grant, however, REM-001 costs to restart the program are not expected to ramp up until the fourth first calendar quarter of 2023. 2024. In addition, during the three months ended December 31, 2023, we received \$198 (2022 - nil) in grant proceeds. Non-cash, share-based compensation expense decreased to \$86 \$23 for the three months ended September 30, 2023 December 31, 2023, from \$140 \$134 for the three months ended September 30, 2022 December 31, 2022.



## General and Administrative

General and administrative expenses were ~~\$1,103~~ \$908 for the three months ended ~~September 30, 2023~~ December 31, 2023, compared to ~~\$1,475~~ \$1,440 for the three months ended ~~September 30, 2022~~ December 31, 2022. A significant portion of the decrease was a result of lower non-cash, share-based compensation expenses and a reduction in professional fees and personnel costs in the current three months compared to the same period in the prior fiscal year. Non-cash, share-based compensation expense decreased to \$180 for the three months ended December 31, 2023, from \$302 for the six months ended December 31, 2022, due to the recognition of higher compensation expense recognized during the three months ended December 31, 2022, for stock options granted in September 2021. Professional fees have decreased in the current quarter compared to the same quarter in the prior fiscal year largely due to a reduction in corporate activity. Personnel costs have decreased in the current quarter compared to the same quarter in the prior fiscal year largely due to a reduction in staff.

## Preferred Share Dividends

For each of the three months ended December 31, 2023, and 2022, we recorded \$2 related to the cash dividend payable to Valent on the Series A Preferred Stock. The dividend has been recorded as a direct increase in accumulated deficit for both periods.

## Comparison of the six months ended December 31, 2023, and December 31, 2022

	Six months ended		Change \$	Change %
	December 31,	December 31,		
	2023	2022		
	\$	\$		
	(in thousands)			
<b>Expenses</b>				
Research and development	1,970	5,230	(3,260)	(62)
General and administrative	2,011	2,915	(904)	(31)
	(3,981)	(8,145)	4,164	
<b>Other income (loss)</b>				
Foreign exchange	(8)	11	(19)	(173)
Interest, net	4	84	(80)	(95)
	(4)	95	(99)	
<b>Net loss</b>	(3,985)	(8,050)	4,065	

## Research and Development

Research and development expenses decreased to \$1,970 for the six months ended December 31, 2023, from \$5,230 for the six months ended December 31, 2022. The decrease was largely attributable to lower clinical development costs and lower non-cash, share-based compensation expenses incurred during the six months ended December 31, 2023, compared to the six months ended December 31, 2022.

Clinical development costs have decreased in the current quarter compared to the same quarter in the prior fiscal year in part due to costs related to the GBM AGILE Study being lower in the six months ended December 31, 2023, compared to the six months ended December 31, 2022. In addition, on October 19, 2022, we announced that we had paused the REM-001 program in order to preserve cash for the development of VAL-083. On June 28, 2023, we announced the restart of the REM-001 program as a result of the awarding of a \$2 million grant, however, REM-001 costs to restart the program are not expected to ramp up until the first calendar quarter of 2024. In

addition, during the six months ended December 31, 2023, we received \$210 (2022 - nil) in grant proceeds. Non-cash, share-based compensation expense decreased to \$109 for the six months ended December 31, 2023, from \$274 for the six months ended December 31, 2022.

General and Administrative

General and administrative expenses were \$2,011 for the six months ended December 31, 2023, compared to \$2,915 for the six months ended December 31, 2022. A significant portion of the decrease was a result of lower non-cash, share-based compensation expenses and a reduction in personnel costs in the current three six months compared to the same period in the prior fiscal year. Non-cash, share-based compensation expense decreased to \$121 \$301 for the three six months ended September 30, 2023 December 31, 2023, from \$378 \$680 for the three six months ended September 30, 2022 December 31, 2022, due to the recognition of higher compensation expense recognized during the three six months ended September 30, 2022 December 31, 2022, for stock options granted in September 2021. Personnel costs have decreased in the current quarter compared to the same quarter in the prior fiscal year largely due to a reduction in staff.

Preferred Share Dividends

For each of the three six months ended September 30, 2023 December 31, 2023, and 2022, we recorded \$2 \$4 related to the cash dividend payable to Valent on the Series A Preferred Stock. In addition, for the six months ended December 31, 2023, we recorded \$173 (2022 - \$362) related to the stock dividend payable to investors on the Series C Preferred Stock. The dividend has dividends have been recorded as a direct increase in accumulated deficit for both periods.

Liquidity and Capital Resources

Three Six months ended September 30, 2023 December 31, 2023, compared to the three six months ended September 30, 2022 December 31, 2022

	Septemb er 30, 2023 \$	Septemb er 30, 2022 \$	Chan ge \$	Chan ge %	December 31, 2023 \$	December 31, 2022 \$	Change \$	Change %
	(in thousands)				(in thousands)			
Cash flows from operating activities	(1,317)	(6,369)	52	(79)	(3,434)	(8,530)	5,096	(60)
Cash flows from investing activities	—	(232)	232	0	(20)	(232)	212	100

Cash flows from financing activities	(2)	1,906	(1,908)	(100)	2,577	1,856	721	39
--------------------------------------	-----	-------	---------	-------	-------	-------	-----	----

### Operating Activities

Net cash used in operating activities decreased to \$1,317 was \$3,434 for the three six months ended September 30, 2023 December 31, 2023, from \$6,369 compared to \$8,530 for the three six months ended September 30, 2022 December 31, 2022. During the three six months ended September 30, 2023 December 31, 2023, and 2022, we reported net losses of \$2,962 \$3,985 and \$4,596, \$8,050, respectively. Changes in adjustments Adjustments to reconcile net loss to net cash used in operating activities for the three six months ended September 30, 2023 December 31, 2023, included stock option expense of \$160 \$325 being recognized during the current period compared to \$518 \$954 in the same period in the prior fiscal year. In addition, during the three six months ended September 30, 2023 December 31, 2023, non-cash expenses of \$47 \$85 were incurred for restricted stock unit expense while no such items were incurred in the three six months ended September 30, 2022 December 31, 2022. The most significant changes in working capital for the three six months ended September 30, 2023 December 31, 2023, were related to a decrease in prepaid expense the use of clinical trial deposit to settle clinical trial expenses of \$961 and deposits settlement of \$1,075 and an increase in accounts payable and accrued liabilities of \$214. \$1,062. The most significant change changes in working capital for the three six months ended September 30, 2022 December 31, 2022, was due to an increase in prepaid expenses and deposits a payment of clinical trial deposit of \$1,700 and an increase in settlement of accounts payable and accrued liabilities of \$331. \$535.

### Investing Activities

Net cash used in investing activities was nil \$20 for the three six months ended September 30, 2023 December 31, 2023, compared to \$232 for the three six months ended September 30, 2022 December 31, 2022, for the purchase of equipment.

### Financing Activities

Net cash received from financing activities was nil \$2,577 for the three six months ended September 30, 2023 December 31, 2023, compared to \$1,856 for the six months ended December 31, 2022. During the three six months ended September 30, 2022 December 31, 2023, we received \$1,908 \$2,476 in net proceeds from sales of shares under our ATM Facility (as defined herein) with A.G.P./Alliance Global Partners ("AGP"), \$105 in net proceeds from the sale of shares under the stock purchase agreement, dated as of August 2, 2022, (the "Purchase Agreement") with Lincoln Park Capital Fund, LLC ("Lincoln Park"), pursuant to which Lincoln Park committed to purchase up to a maximum of \$20,000 of shares of the Company's common stock. stock, and \$210 in clinical grant funding. During the six months ended December 31, 2022, we received \$1,860 in net proceeds from the sale of shares under the Lincoln Park Purchase Agreement.

## Going Concern and Capital Expenditure Requirements

### Going Concern and Management Plans

(See note 1 to the condensed consolidated interim financial statements)

The condensed consolidated financial statements have been prepared on a going concern basis, which assumes that we will continue our operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business.

For the ~~three~~ ~~six~~ months ended ~~September 30, 2023~~ ~~December 31, 2023~~, we reported a loss of ~~\$2,962~~ ~~\$3,985~~ and a negative cash flow from operations of ~~\$1,317~~ ~~\$3,434~~. We had an accumulated deficit of ~~\$154,512~~ ~~\$155,537~~ and had cash and cash equivalents of ~~\$216~~ ~~\$658~~ as of ~~September 30, 2023~~ ~~December 31, 2023~~. We are in the clinical stage and have not generated any revenues to date. We do not have the prospect of achieving revenues until such time that our product ~~candidates are~~ ~~candidate is~~ commercialized, or partnered, which may not ever occur. On August 2, 2022, we entered into the Purchase Agreement under which we received approximately ~~\$1,903~~ ~~\$2,008~~ in net proceeds as of ~~September 30, 2023~~ ~~December 31, 2023~~, for the issuance of an aggregate of ~~262~~ ~~662~~ shares of common stock under the Purchase Agreement. On October 9, 2023, we received stockholder approval to issue 20% or more of our outstanding shares as of the date we entered into the Purchase Agreement with Lincoln Park. In addition, on June 28, 2023, we announced that we had been awarded approximately \$2.0 million in grant funding for our REM-001 project.

On September 19, 2023, we entered into a Sales Agreement, (the "Sales Agreement") with ~~A.G.P./Alliance Global Partners (the "Agent")~~ ~~AGP~~ pursuant to which ~~we~~ ~~the Company~~ may offer and sell, from time to time, through ~~the Agent, AGP~~, as sales agent and/or principal, shares of ~~our~~ common stock having an aggregate offering price of up to ~~\$2.85 million~~ ~~\$10.9 million~~ (the "ATM Facility"). ~~Subsequent to September 30, 2023~~ ~~From October 31, 2023, until December 31, 2023~~, we raised ~~\$968~~ ~~\$2,579~~ in net proceeds from the sale of ~~1,629~~ ~~8,013~~ shares of our common stock under ~~our~~ ~~the~~ ATM Facility.

23

~~From January 1, 2024, to February 12, 2024, we raised an additional \$6,108 in net proceeds from the sale of 28,870 shares of our common stock under the ATM Facility.~~

Even with the proceeds from the grant funding, the stock purchase financing, and the ATM sales, we will require significant additional funding to maintain ~~its~~ ~~our~~ clinical trials, research and development projects, and for general operations. These circumstances indicate substantial doubt exists about our ability to continue as a going concern within one year from the date of filing of these condensed consolidated financial statements.

Consequently, management is pursuing various financing alternatives to fund our operations in the short and long term and so we can continue as a going concern. In addition, we ~~will evaluate~~ ~~have initiated a~~ ~~wide process to explore and review a~~ range of strategic ~~options aimed at potentially~~ ~~alternatives focused on~~ maximizing shareholder value. Management plans to secure the necessary financing through potential additional proceeds from our Purchase Agreement with Lincoln Park, the ATM Facility, grant funding, and the issue of new equity and/or the entering into of strategic partnership arrangements. Our ability to raise additional capital is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence. We may not be able to raise sufficient additional capital and may tailor our drug candidate development program based on the amount of funding we are able to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful.

The condensed consolidated financial statements do not give effect to any adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. Such adjustments could be material. Our future funding requirements will depend on many factors, including but not limited to:

- the rate of progress and cost of our clinical studies, preclinical studies and other discovery and research and development activities;
- the costs associated with establishing manufacturing and commercialization capabilities;
- the costs of acquiring or investing in businesses, product candidates and technologies;

- the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;
- the costs and timing of seeking and obtaining FDA and other regulatory approvals;
- the effect of competing technological and market developments;
- the economic and other terms and timing of any collaboration, licensing or other arrangements into which we may enter; and
- the impact of us being a public entity.

Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through public or private equity offerings, or strategic collaborations. The sale of equity and convertible debt securities may result in dilution to our stockholders and certain of those securities may have rights senior to those of our shares of capital stock. If we raise additional funds through the issuance of preferred stock, convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict our operations. Any other third-party funding arrangement could require us to relinquish valuable rights. Economic conditions may affect the availability of funds and activity in equity markets. We do not know whether additional funding will be available on acceptable terms, or at all. If we are not able to

25

secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more of our clinical trials or research and development programs or make changes to our operating plan, file for bankruptcy protection or pursue a dissolution of the Company and liquidation of all of our remaining assets. In such an event, the amount of cash available for distribution to our shareholders, if any, will depend heavily on the timing of such decision, as with the passage of time the amount of cash available for distribution will be reduced as we continue to fund our operations. We cannot provide assurance as to the amount of cash that will be available to distribute to shareholders, if any, after paying our debts and other obligations and setting aside funds for reserves, nor as to the timing of any such distribution, if any.

### Critical Accounting Policies and Estimates

The preparation of financial statements, in conformity with generally accepted accounting principles in the United States, requires companies to establish accounting policies and to make estimates that affect both the amount and timing of the recording of assets, liabilities, revenues and expenses. Some of these estimates require judgments about matters that are inherently uncertain and therefore actual results may differ from those estimates.

A detailed presentation of all of our significant accounting policies and the estimates derived therefrom is included in Note 2 to our consolidated financial statements for the year ended June 30, 2023, contained in our [Annual Report on Form 10-K](#) filed with the SEC on September 18, 2023. While all of the significant accounting policies are important to our consolidated financial statements, the following accounting policies and the estimates derived therefrom are critical:

- ☐ Fair value of financial instruments
- ☐ Accruals for research and development expenses and clinical trials

24

### Fair value of financial instruments

We recognize compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the statement of operations over the service period based on a measurement of fair value for each stock-based award. Prior to our adoption of Accounting Standards Update 2018-07, *Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting* ("ASU 2018-07"), stock options granted to non-employee consultants were revalued at the end of each reporting period until vested using the Black-Scholes option-pricing model and the changes in their fair value were recorded as adjustments to expense over the related vesting period. For the **three six** months ended **September 30, 2023** **December 31, 2023**, and 2022, the determination of grant-date fair value for stock option awards was estimated using the Black-Scholes model which includes variables such as the expected volatility of our share price, the anticipated exercise behavior of its grantee, interest rates, and dividend yields. For the **three six** months ended **September 30, 2023** **December 31, 2023**, and 2022, we utilized the plain vanilla method to determine the expected life of stock options. These variables are projected based on our historical data, experience, and other factors. Changes in any of these variables could result in material adjustments to the expense recognized for share-based payments. Such value is recognized as expense over the requisite service period, net of actual forfeitures, using the accelerated attribution method. We recognize forfeitures as they occur. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results, or updated estimates, differ from current estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.

For the **three six** months ended **September 30, 2023** **December 31, 2023**, and 2022, we issued stock options to our officers. The determination of grant-date fair value for options granted was estimated using the Black-Scholes model which includes variables such as the expected volatility of our share price, interest rates, dividend yields, and the term of the option.

### Accruals for research and development expenses and clinical trials

As part of the process of preparing our financial statements, we are required to estimate our expenses resulting from our obligations under contracts with vendors, clinical research organizations and consultants, and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment terms that do not match the periods over which materials or services are provided under such contracts. Our objective is to reflect the appropriate expenses in our financial statements by matching those expenses with the period in which services are performed and efforts are expended. We account for these expenses according to the timing of various aspects of the expenses. We determine accrual estimates by taking into account discussion with applicable personnel and outside service providers as to the progress of clinical trials, or the services completed. During the course of a clinical trial, we adjust our clinical expense recognition if actual results differ from our estimates. We make estimates of our accrued expenses as of each balance sheet date based on the facts and circumstances known to us at that time. Our clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party vendors. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low for any particular period. For the **three six** months ended **September 30, 2023** **December 31, 2023**, and 2022, there were no material adjustments to our prior period estimates of accrued expenses for clinical trials.

## Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

25 27

---

## Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not required for a smaller reporting company.

## Item 4. Controls and Procedures.

(a) *Evaluation of Disclosure Controls and Procedures.* Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e)) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) as of the end of the period covered by this Form 10-Q, have has concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

(b) *Changes in Internal Controls.* There were no changes in our internal control over financial reporting, identified in connection with the evaluation of such internal control that occurred during the quarter ended September 30, 2023 December 31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

26 28

---

## PART II - OTHER INFORMATION

### Item 1. Legal Proceedings.

There are no legal proceedings the Company is party to or any of its property is subject to.

### Item 1A. Risk Factors.



In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended June 30, 2023 filed with the Securities SEC on September 18, 2023 and Exchange Commission our Quarterly Report on September 18, 2023 Form 10-Q filed with the SEC on November 13, 2023 (the "Prior 10-Q"), which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K may not be the only risks facing the Company. Additional risks and uncertainties not currently known to the Company or that the Company currently deems to be immaterial also may materially adversely affect the Company's business, financial condition and/or operating results.

There were no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K and in our Prior 10-Q except as noted below.

***We are not currently in compliance with the continued listing requirements for The Nasdaq Capital Market. If we do not regain compliance and continue to meet the continued listing requirements, our common stock may be delisted from The Nasdaq Capital Market, which could affect the market price and liquidity for our common stock and reduce our ability to raise additional capital.***

Our common stock is listed on The Nasdaq Capital Market. In order to maintain that listing, we must satisfy minimum financial and other requirements including, without limitation, the minimum stockholders' equity requirement and minimum bid price requirements for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders' equity of at least \$2,500,000 (the "Stockholders' Equity Requirement"). Nasdaq Listing Rule 5550(a)(2) requires companies listed on The Nasdaq Capital Market to maintain a minimum bid price of \$1 per share (the "Minimum Bid Price Requirement").

On September 20, 2023, the Nasdaq Staff notified us that we did not comply with the Stockholders' Equity Requirement (the "Notice"). Pursuant to the Notice, Nasdaq has given us until November 6, 2023 to submit to Nasdaq we submitted a plan to regain compliance. If our plan is accepted, Nasdaq may grant compliance on November 6, 2023, and received an extension of up to 180 calendar days from the date of the Notice, or March 18, 2024, to evidence compliance. The Notice has no immediate effect on the listing of our common stock and our common stock continues to trade on The Nasdaq Capital Market under the symbol "KTRA," subject to our compliance with the other continued listing requirements.

On December 13, 2023, the Nasdaq staff notified us that we did not comply with the Minimum Bid Price Requirement (the "Bid Price Notice"). Pursuant to the Bid Price Notice, we have 180 calendar days from the date of the Bid Price Notice, or June 10, 2024, to regain compliance for a minimum of ten consecutive business days.

We will continue to monitor our stockholders' equity and bid price and may, if appropriate, consider implementing available options to regain compliance with the Stockholders' Equity Requirement and the Minimum Bid Price Requirement. There can be no assurance that we will be able to regain compliance with the Stockholders' Equity Requirement or the Minimum Bid Price Requirement or maintain compliance even if we implement an option that regains our compliance.

If we fail to regain compliance with the Stockholders' Equity Requirement or the Minimum Bid Price Requirement, or to meet the other applicable continued listing requirements for The Nasdaq Capital Market in the future, our common stock may be delisted and trade on the OTC Markets Group Inc. or other small trading markets, which could reduce the liquidity of our common stock materially and result in a corresponding material reduction in the price of our common stock as well as reduce our ability to raise additional capital. In addition, if our common stock is delisted from Nasdaq and the trading price remains below \$5.00 per share, trading in our common stock might also become subject to the requirements of certain rules promulgated under the Exchange Act, which require additional disclosure by broker-



dealers in connection with any trade involving a stock defined as a “penny stock” (generally, any equity security not listed on a national securities exchange or quoted on Nasdaq that has a market price of less than \$5.00 per share, subject to certain exceptions).

**Economic uncertainty may affect our access to capital and/or increase the costs of such capital.**

Global economic conditions continue to be volatile and uncertain due to, among other things, consumer confidence in future economic conditions, fears of recession and trade wars, the price of energy, fluctuating interest rates, the availability and cost of consumer credit, the availability and timing of government stimulus programs, levels of unemployment, increased inflation, tax rates, and the war between Ukraine and Russia which began in February 2022, and Israel and Hamas, which began in October 2023 and which threatens to spread to other Middle Eastern countries. These conditions remain unpredictable and create uncertainties about our ability to raise capital in the future. In the event required capital becomes unavailable in the future, or more costly, it could have a material adverse effect on our business, future results of operations, and financial condition.

**Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities.**

27

None.

29

**Item 3. Defaults Upon Senior Securities.**

None.

**Item 4. Mine Safety Disclosures.**

Not applicable.

**Item 5. Other Information.**

On February 13, 2024, we sent an Opt-Out Notice to Valent under the Valent Assignment Agreement whereby we assigned all rights, title and interest in and to the patents for VAL-083 to Valent. As a result, we granted Valent a non-exclusive, fully-paid, royalty-free, perpetual, worldwide and non-transferable license, subject to limited exceptions. We are entitled to receive royalties from Valent's subsequent commercialization of VAL-083 equal to 5% of Valent Net Sales (as defined in the Valent Assignment Agreement).

None. 30

28

## Item 6. Exhibits.

The exhibits listed below are filed or furnished as part of this Quarterly Report on Form 10-Q.

### EXHIBIT INDEX

Exhibit Number	Description
10.1	<a href="#">Sales Agreement, dated September 19, 2023, by and between A.G.P./Alliance Global Partners and Kintara Therapeutics, Inc. (incorporated by reference to Exhibit 1.1 to the Company's Current Report on Form 8-K filed with the SEC on September 19, 2023).</a>
31.1	<a href="#">Certification of principal executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</a>
31.2	<a href="#">Certification of principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</a>
32.1	<a href="#">Certification of principal executive officer and financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**</a>
EX-101.INS	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document*
EX-101.SCH	Inline XBRL Taxonomy Extension Schema Document*
EX-101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document*
EX-101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document*
EX-101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document*
EX-101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document*
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

\* Filed herewith

\*\* The certification furnished in Exhibit 32.1 hereto is deemed to accompany this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**Kintara Therapeutics, Inc.**

Date: **November 13, 2023** February 14, 2024

By: /s/ Robert E. Hoffman

Robert E. Hoffman

Chief Executive Officer and Interim Chief

Financial Officer

(Principal Executive Officer and Principal

Financial and Accounting Officer)

**30 32**

---

**Exhibit 31.1**

### CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Robert E. Hoffman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Kintara Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
- (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
- (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 13, 2023 February 14, 2024

By: /s/ Robert E. Hoffman

**Robert E. Hoffman**  
**Chief Executive Officer**  
**(Principal Executive Officer)**

**CERTIFICATION PURSUANT TO  
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,  
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Robert E. Hoffman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Kintara Therapeutics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

By: /s/ Robert E. Hoffman

By: /s/ Robert E. Hoffman

REFINITIV 



## DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.